Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.51
-$0.08(-1.45%)
At close: 4:00 PM EDT
$5.51
-$0.08(-1.45%)
Day’s Range― - ―
52-Week Range$2.68 - $7.01
Previous Close$5.57
Volume3.79M
Average Volume (3M)1.93M
Market Cap
$1.17B
Enterprise Value$1.42K
Total Cash (Recent Filing)$173.03M
Total Debt (Recent Filing)$30.11M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding205,460,020
10 Day Avg. Volume1,761,044
30 Day Avg. Volume1,928,563
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.17Price Target Upside102.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$2.94M
Bulls Say, Bears Say
Bulls Say
Rare-disease Focused PipelineSavara's concentrated focus on inhaled molgramostim for aPAP is a durable strategic asset: orphan indications often allow expedited regulatory pathways, pricing leverage and concentrated clinical expertise. If approved, this creates a defensible, specialty commercial niche that supports long-term revenue potential.
Regulatory Submissions Nearing CommercializationHaving regulatory filings active in the U.S., EU and U.K. represents a structural transition from R&D to commercialization readiness. Approvals in major markets would change the company's cash-generation profile, justify commercial investment, and materially alter long-term growth prospects over the coming months.
Manageable LeverageLow reported leverage (debt-to-equity ~0.17) gives Savara relative financial flexibility compared with more highly leveraged peers. This preserves optionality to fund late-stage activities or a commercial launch through debt or structured financings without immediate solvency pressure, a durable strength for upcoming milestones.
Bears Say
No Commercial RevenueSavara currently generates no product revenue while net losses have widened materially to roughly -$129M TTM. Persistent absence of commercial receipts means the company must rely on external capital or partnerships to fund operations, increasing execution risk and creating sustained pressure on financing needs over multiple quarters.
High And Accelerating Cash BurnOperating cash flow has accelerated to roughly -$107M TTM, indicating real liquidity erosion rather than non-cash losses. Sustained, rising cash burn reduces runway, forces frequent financing or strategic trade-offs, and can delay or complicate commercialization and development plans if additional capital is not secured.
Material Dilution Risk From Share ExpansionsShareholder-approved doubling of authorized shares and an 18.9M-share increase to the incentive pool structurally raises the company's capacity to issue equity. While this supports future financings and compensation, it increases dilution risk for existing holders and can negatively affect long-term per-share economics if used to cover recurring funding shortfalls.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.68 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.17B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Aug 11, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.141 by -$0.019.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.16.
How many shares outstanding does Savara have?
Savara has 205,460,020 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.141. Following the earnings report the stock price went up 2.334%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (102.66% Upside)
$11.17 (102.66% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.33%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.17
▲(102.66% Upside)
Technical Analysis
Ownership Overview
3.08% Insiders
7.48% Mutual Funds
8.82% Other Institutional Investors
69.12% Public Companies and
Individual Investors